Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Orelabrutinib

From Wikipedia, the free encyclopedia
Drug for treatment of cancer

Pharmaceutical compound
Orelabrutinib
Clinical data
Trade names宜诺凯
Other namesICP-022; ICP022
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 2-(4-Phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide
CAS Number
PubChemCID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC26H25N3O3
Molar mass427.504 g·mol−1
3D model (JSmol)
  • C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4
  • InChI=1S/C26H25N3O3/c1-2-24(30)29-16-14-18(15-17-29)23-13-12-22(26(27)31)25(28-23)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-13,18H,1,14-17H2,(H2,27,31)
  • Key:MZPVEMOYADUARK-UHFFFAOYSA-N

Orelabrutinib is a drug for the treatment of cancer.

In China, it is approved for patients withmantle cell lymphoma (MCL) andchronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), who have received at least one treatment in the past.[1]

Orelabrutinib is aninhibitor ofBruton's tyrosine kinase.[2]

References

[edit]
  1. ^Dhillon S (March 2021). "Orelabrutinib: First Approval".Drugs.81 (4):503–507.doi:10.1007/s40265-021-01482-5.PMID 33704654.
  2. ^Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, et al. (August 2023)."Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study".Blood Advances.7 (16):4349–4357.doi:10.1182/bloodadvances.2022009168.PMC 10432605.PMID 37078706.
CImonoclonal antibodies ("-mab")
Receptor tyrosine kinase
Others for solid tumors
Leukemia/lymphoma
Other
Tyrosine kinase inhibitors ("-nib")
Receptor tyrosine kinase
Non-receptor
Other


Stub icon

Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Orelabrutinib&oldid=1232712005"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp